These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases. Calsolaro V; Edison P CNS Drugs; 2015 Dec; 29(12):1023-39. PubMed ID: 26666230 [TBL] [Abstract][Full Text] [Related]
47. Nano-medicine Improving the Bioavailability of Small Molecules for the Prevention of Neurodegenerative Diseases. Di Martino P; Censi R; Gigliobianco MR; Zerrillo L; Magnoni F; Agas D; Quaglia W; Lupidi G Curr Pharm Des; 2017; 23(13):1897-1908. PubMed ID: 28025942 [TBL] [Abstract][Full Text] [Related]
48. Nanoneurotoxicity to nanoneuroprotection using biological and computational approaches. Iqbal A; Ahmad I; Khalid MH; Nawaz MS; Gan SH; Kamal MA J Environ Sci Health C Environ Carcinog Ecotoxicol Rev; 2013; 31(3):256-84. PubMed ID: 24024521 [TBL] [Abstract][Full Text] [Related]
49. The active Hsc70/tau complex can be exploited to enhance tau turnover without damaging microtubule dynamics. Fontaine SN; Martin MD; Akoury E; Assimon VA; Borysov S; Nordhues BA; Sabbagh JJ; Cockman M; Gestwicki JE; Zweckstetter M; Dickey CA Hum Mol Genet; 2015 Jul; 24(14):3971-81. PubMed ID: 25882706 [TBL] [Abstract][Full Text] [Related]
50. Biological metals and metal-targeting compounds in major neurodegenerative diseases. Barnham KJ; Bush AI Chem Soc Rev; 2014 Oct; 43(19):6727-49. PubMed ID: 25099276 [TBL] [Abstract][Full Text] [Related]
51. Modulators of Acetylcholinesterase Activity: From Alzheimer's Disease to Anti-Cancer Drugs. Lazarevic-Pasti T; Leskovac A; Momic T; Petrovic S; Vasic V Curr Med Chem; 2017; 24(30):3283-3309. PubMed ID: 28685687 [TBL] [Abstract][Full Text] [Related]
52. ROCK in CNS: Different Roles of Isoforms and Therapeutic Target for Neurodegenerative Disorders. Chong CM; Ai N; Lee SM Curr Drug Targets; 2017; 18(4):455-462. PubMed ID: 27033194 [TBL] [Abstract][Full Text] [Related]
53. Biomarkers in Neurodegenerative Diseases. Jeromin A; Bowser R Adv Neurobiol; 2017; 15():491-528. PubMed ID: 28674995 [TBL] [Abstract][Full Text] [Related]
54. A novel p38 alpha MAPK inhibitor suppresses brain proinflammatory cytokine up-regulation and attenuates synaptic dysfunction and behavioral deficits in an Alzheimer's disease mouse model. Munoz L; Ralay Ranaivo H; Roy SM; Hu W; Craft JM; McNamara LK; Chico LW; Van Eldik LJ; Watterson DM J Neuroinflammation; 2007 Sep; 4():21. PubMed ID: 17784957 [TBL] [Abstract][Full Text] [Related]
55. Barrier function in the peripheral and central nervous system-a review. Reinhold AK; Rittner HL Pflugers Arch; 2017 Jan; 469(1):123-134. PubMed ID: 27957611 [TBL] [Abstract][Full Text] [Related]
56. Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders. Mattson MP Neuromolecular Med; 2003; 3(2):65-94. PubMed ID: 12728191 [TBL] [Abstract][Full Text] [Related]
57. Metallothioneins and the central nervous system: from a deregulation in neurodegenerative diseases to the development of new therapeutic approaches. Bolognin S; Cozzi B; Zambenedetti P; Zatta P J Alzheimers Dis; 2014; 41(1):29-42. PubMed ID: 24577478 [TBL] [Abstract][Full Text] [Related]
58. The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease. Savelieff MG; DeToma AS; Derrick JS; Lim MH Acc Chem Res; 2014 Aug; 47(8):2475-82. PubMed ID: 25080056 [TBL] [Abstract][Full Text] [Related]